Omadacycline in Vitro Activity Against Bacillus anthracis

Efficacy of Drug Regimens Containing Omadacycline in a Murine Model of Mycobacterium avium Chronic Lung Infection

Microbiological Outcomes of Oral Omadacycline Treatment in Adults with Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium abscessus complex (MABc): Results from a Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center Trial

Omadacycline outcomes in community-acquired bacterial pneumonia: pooled efficacy and safety from the Phase 3 OPTIC and OPTIC-2 trials.

Omadacycline was Shown to Preserve the Microbiome in a Murine Model of Post-Influenza MRSA Pneumonia

Health-related quality-of-life outcomes in OPTIC-2: A randomized, controlled, Phase 3b trial of omadacycline vs. moxifloxacin in community-acquired bacterial pneumonia

In Vitro Activity of Omadacycline and Comparator Agents Against Periodontal Pathogens

Susceptibility of Omadacycline in Bone and Joint Infections: Pathogen Susceptibility and Regimen Decisions from an Ongoing Randomized Controlled Trial

Pooled Microbiological Outcomes from the Phase 3, Randomized OPTIC and OPTIC-2 Trials of Omadacycline vs Moxifloxacin in Community-Acquired Bacterial Pneumonia

Real-world Efficacy and Safety of Omadacycline in Immunocompromised Patients

Tigecycline as a Surrogate for Omadacycline Susceptibility in Enterococcus faecalis and Enterococcus faecium

Omadacycline for Community-acquired Bacterial Pneumonia (OPTIC-2): A Phase 3b Randomized, Double-blind, Multicenter, Controlled, Noninferiority Trial

A Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Omadacycline in Adults With Nontuberculous Mycobacterial Pulmonary Disease (NTM PD) Caused by Mycobacterium Abscessus

Prescription Patterns among Outpatients with Antibiotic Failure/Intolerance in the Treatment ​ of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): A 2020 to 2022 Retrospective Cohort Study​

Omadacycline for Skin and Soft Tissue Infections: A Multicenter Retrospective Analysis of Efficacy and Safety in Real-World Clinical Practice

Omadacycline for Skin and Soft Tissue Infections: A Multicenter Retrospective Analysis of Efficacy and Safety in Real-World Clinical Practice

Clinical Efficacy and Safety of Omadacycline in the Treatment of Enterococcal Infections

Activity of omadacycline against multidrug-resistant and molecularly characterized Acinetobacter baumannii-calcoaceticus complex clinical isolates from United States hospitals (2020–2023)

Omadacycline demonstrated efficacy as both therapeutic treatment and post-exposure prophylaxis against inhalation anthrax and pneumonic plague in cynomolgus macaques

Clinical and microbiological outcomes of omadacycline for pulmonary Mycobacterium abscessus complex

Evaluation of Fecal Pharmacokinetics and Metagenomic Changes Following the Administration of Intravenous Omadacycline to Healthy Subjects

Current Prescribing Practices and Guideline Concordance for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) among Outpatient and Urgent Care Visits

In vitro activity of omadacycline and comparator agents against a collection of Neisseria gonorrhoeae urine isolates collected from the United States during 2018-2020

Safety of Omadacycline Versus Standard-of-Care Oral Antibiotic Treatment for Bone and Joint Infections: Interim Results From an Open-Label, Non-Inferiority, Randomized Controlled Trial

Omadacycline is Active Against Multidrug Resistant Bacillus Anthracis Strains Resistant to Tetracyclines

In Vitro Interaction of Omadacycline in Combination with Melatonin against Carbapenemase producing Klebsiella pneumoniae

Evaluation of Omadacycline Treatment for Osteomyelitis

Omadacycline alone and in combination as a treatment option for Mycobacterium avium infections

Minimum inhibitory concentrations (MICs) of tigecycline correlate strongly with those of omadacycline

Real-World Outpatient Use of Omadacycline for Bone and Joint Infections

Early Experience With Omadacycline For The Treatment Of Diabetic Foot Infections

Activity of Omadacycline and Comparators Against 876 Bacterial Clinical Isolates from Patients with Bone and Joint Infections in the United States and Europe (2015–2022)

Omadacycline for the Treatment of Non-Pulmonary Mycobacterial Infections: a Single-Center Retrospective Review

Omadacycline is Efficacious in a Treatment Model of Inhalational Anthrax in New Zealand White Rabbits

Omadacycline Efficacy in a Post-Exposure Prophylaxis Mouse Model of Inhalational Anthrax Caused by Ciprofloxacin-Resistant Bacillus anthracis

In vitro activity of omadacycline and comparator agents against 485 infrequently encountered bacterial pathogens from the SENTRY surveillance programmme

Real-World Use of Omadacycline in Physician Office Infusion Centers (POICs)

A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections

Preclinical evaluation of omadacycline for potential as a drug to treat Acinetobacter baumannii and Klebsiella pneumoniae infections in combat wounds

In Vitro Activity of Omadacycline against Chlamydia trachomatis Serovars

Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of omadacycline in adults with Mycobacterium abscessus complex (MABc) pulmonary disease

Omadacycline in Vitro Activity Against Bacillus Anthracis

Omadacycline in Female Adults with Acute Pyelonephritis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study

Omadacycline in Female Adults with Cystitis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study

Pharmacokinetic-Pharmacodynamic (PK-PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data from Omadacycline (OMC)-Treated Patients

Pharmacokinetic‐Pharmacodynamic (PK‐PD) Analyses for Cardiac Endpoints Using Clinical Study Data from Omadacycline (OMC)‐Treated Patients

Investigating the Interaction between Omadacycline and Other Antibacterial Agents against Gram-Positive and GramNegative Bacteria